Denali Therapeutics to Present Key Data on Rare Disease Programs at WORLDSymposium 2026
Event summary
- Denali will present Phase 1/2 data on tividenofusp alfa (DNL310) for Hunter syndrome, under FDA Priority Review with decision due April 5, 2026.
- Preliminary Phase 1/2 data on DNL126 for Sanfilippo syndrome type A to be featured in oral presentation.
- Phase 1 study design for DNL952 in Pompe disease and supporting preclinical data to be presented.
- Company to host satellite symposium on MPS II patient care on February 5, 2026.
The big picture
Denali's presentations at WORLDSymposium 2026 highlight its progress in overcoming the blood-brain barrier for enzyme replacement therapies. The company's TransportVehicle™ platform represents a strategic advantage in treating neurological manifestations of rare diseases, positioning Denali as a key player in the lysosomal storage disorder space. The upcoming FDA decision on tividenofusp alfa could validate this approach and unlock significant commercial potential.
What we're watching
- Regulatory Outcome
- Whether the FDA will approve tividenofusp alfa by the April 5, 2026 PDUFA date, marking Denali's first commercial product.
- Clinical Validation
- How the Phase 1/2 data for DNL126 in Sanfilippo syndrome type A will position the program against competitors.
- Platform Expansion
- The pace at which Denali can advance its TransportVehicle™ platform across multiple lysosomal storage disorders.
Related topics